AUTHOR=Guan Wen-Long , Qiu Miao-Zhen , He Cai-Yun , Yang Li-Qiong , Jin Ying , Wang Zhi-Qiang , Li Yu-Hong , Xu Rui-Hua , Wang Feng-Hua TITLE=Clinicopathologic Features and Prognosis of BRAF Mutated Colorectal Cancer Patients JOURNAL=Frontiers in Oncology VOLUME=10 YEAR=2020 URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.563407 DOI=10.3389/fonc.2020.563407 ISSN=2234-943X ABSTRACT=

Background:BRAF^V600E mutation is associated with poor prognosis of colorectal cancer (CRC) patients, but the comparison of clinic-pathologic features between V600E and non-V600E mutation was not well-known in CRC patients. The aim of this study is to evaluate the clinical and pathological features, prognostic value of BRAF mutations in CRC.

Methods: We conducted a retrospective study to characterize the clinical and pathological features and survival of patients with BRAF mutated CRC. Patients were classified according to BRAF status as BRAF^V600E mutation and non-V600E mutations. Difference of characteristics and survival between the two groups was analyzed.

Results: There was no significant difference in gender, family history, location of primary tumor, metastatic sites between patients with BRAF-V600E mutation and non-V600E mutations. Patients with V600E mutation were younger than those with non-V600E mutations (p = 0.002). Patients with BRAF^V600E mutation showed a poorer outcome than those with non-V600E mutations (23.1 vs. 49.9 months, respectively, p = 0.0024). Lack of CDX2 expression was associated with worse prognosis (mOS: 9.4 m vs. not reached, respectively, p = 0.016). Status of V600E mutation did not affect the mPFS and ORR of first-line or second-line treatment.

Conclusion:BRAF^V600E mutation defines a distinct subgroup of CRC with worse prognosis. Lack of CDX2 expression is associated with poor OS. Status of V600E mutation did not affect the mPFS of first-line or second-line treatment.